WL6.DE : Summary for WILEX AG O.N. - Yahoo Finance

U.S. Markets close in 3 hrs.

Wilex AG (WL6.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
2.56-0.04 (-1.58%)
At close: 5:36PM CET
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close2.60
Bid0.00 x 57300
Ask0.00 x 225000
Day's Range2.56 - 2.60
52 Week Range1.45 - 3.16
Avg. Volume13,741
Market Cap32.17M
PE Ratio (TTM)-3.99
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuterslast month

    Nordic Nanovector sees interest in its Non-Hodgkin Lymphoma treatment

    "We talk a lot with companies, and as the data improves and the company develops, the more interest we have, that's for sure," chief executive officer Luigi Costa told Reuters. Nanovector is currently preparing a final test phase for its Betalutin drug candidate, a treatment for Non-Hodgkin Lymphoma (NHL) designed to attach itself to tumours in a novel way before killing them with a dose of radiation.

  • WILEX AG :WL6-DE: Earnings Analysis: Q1, 2016 By the Numbers
    Capital Cube11 months ago

    WILEX AG :WL6-DE: Earnings Analysis: Q1, 2016 By the Numbers

    Click here to see latest analysisWILEX AG reports financial results for the quarter ended February 29, 2016.HighlightsNarrowing of operating (EBIT) margins contributed to decline in earnings, despite some positive contribution from one-time items.The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:2015-02-282015-05-312015-08-312015-11-302016-02-29Relevant Numbers (Quarterly)Revenues (mil)0.430.930.350.590.46Revenue […] (Read more...) The post WILEX AG :WL6-DE: Earnings Analysis: Q1, 2016 By the Numbers appeared first on CapitalCube.

  • We're sorry this is all we were able to find about this topic.